Target-specific cancer treatment: chronic granulocytic leukemia as a model

REFERENCES

• Atallah , E. , Talpaz , M. , O'Brien , S. , Rios , M. B. , Guo , J. Q. , Arlinghaus , R. , Fernandes-Reese , S. and Kanarjian , H. 2002 . Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy . Cancer , 94 : 2996 – 2999 .
   PubMed Web of Science ®Google Scholar
• Bagby , G.C. Jr. 2003 . Genetic basis of Fanconi anemia . Current Opinion in Hematology , 10 : 68 – 76 .
   PubMed Web of Science ®Google Scholar
• Barnett , M. J. , Eaves , C. J. , Phillips , G. L. , Gascoyne , R. D. , Hogge , D. E. , Horsman , D. E. , Humphries , R. K. , Klingemann , H. G. , Lansdorp , P. M. and Nantel , S. H. 1994 . Autografting with cultured marrow in chronic myeloid leukemia: results of a pilot study . Blood , 84 : 724 – 732 .
   PubMed Web of Science ®Google Scholar
• Carella , A. M. , Podesta , M. , Frassoni , F. , Raffo , M. R. , Pollicardo , N. , Pungolino , E. , Vimercati , R. , Sessarego , M. , Parodi , C. , Rabitti , C. , Ferrero , R. , Benvenuto , F. , Figari , O. , Carlier , P. , Levcasic , G. , Valbonesi , M. , vitale , V. , Giordano , D. , Pierluigi , D. , Nati , S. , Guerracio , A. , Rosso , C. and Saglio , G. 1993 . Collection of ‘normal’ blood repopulating cells during early hemopoietic recovery after intensive conventional chemotherapy in chronic myelogenous leukemia . Bone Marrow Transplantation , 12 : 167 – 271 .
   PubMedGoogle Scholar
• Champlin , R. , Khouri , I. , Shimoni , A. , Gajewski , J. , Kornblau , S. , Molldrem , J. , Ueno , N. , Giralt , S. and Anderlini , P. 2000 . Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy . British Journal of Haematology , 111 : 18 – 29 .
   PubMed Web of Science ®Google Scholar
• Chase , A. , Parker , S. , Kaede , J. , Sivalingam , R. , Cross , N. C. and Goldman , J. M. 2000 . Absence of host-derived cells in the blood of patients in remission after allografting for chronic myeloid leukemia . Blood , 96 : 777 – 778 .
   PubMedGoogle Scholar
• Chiusolo , P. , Sica , S. , Laurenti , L. , Piccirillo , N. , Giordano , G. and Leone , G. 2000 . Fatal bone marrow aplasia during interferon-α treatment in chronic myelogenous leukemia . Haematologica , 85 : 212
   PubMedGoogle Scholar
• Chomienne , C. , Fenaux , P. and Degos , L. 1996 . Retinoid differentiation therapy in promyelocytic leukemia . FASEB Journal , 10 : 938 – 939 .
   PubMedGoogle Scholar
• Chronic Myeloid Leukaemia Trialists' Collaborative Group . 2000. . Hydroxyurea versus busulphan for chronic myeloid leukaemia: an individual patient data meta-analysis of three randomized trials . British Journal of Haematology , 110 : 573 – 576 .
   PubMedGoogle Scholar
• Druker , B. J. and Lydon , N. B. 2000 . Lessons learned from the development of an ABL tyrosine kinase inhibitor for chronic myelogenous leukemia . Journal of Clinical Investigation , 105 : 3 – 7 .
   PubMed Web of Science ®Google Scholar
• Druker , B. J. , Talpaz , M. , Resta , D. J. , Peng , B. , Buchdunger , E. , Ford , J. M. , Lydon , N. B. , Kantarjian , H. , Capdeville , R. , Ohno-Jones , S. and Sawyers , C. L. 2001 . Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia . New England Journal of Medicine , 344 : 1031 – 1037 .
   PubMed Web of Science ®Google Scholar
• Eaves , A. C. , Barnett , M. J. , Ponchio , L. , Cashman , J. D. , Petzer , A. L. and Eaves , C. J. 1998 . Differences between normal and CML stem cells: potential targets for clinical exploitation . Stem Cells , 16 ( Suppl.1 ) : 77 – 83 .
   PubMedGoogle Scholar
• Fang , G. , Kim , C. N. , Perkins , C. L. , Ramadevi , N. , Winton , E. , Wittmann , S. and Bhalla , K. N. 2000 . CGP57148B (STI-571) induced differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs . Blood , 96 : 2246 – 2253 .
   PubMed Web of Science ®Google Scholar
• Gaal , K. and Arber , D. A. 2000 . Chronic myelogenous leukemia . Laboratory Medicine , 31 : 557 – 562 .
   Google Scholar
• Gaziev , D. , Galimberti , M. , Polchi , P. , Angelucci , E. , Giardini , C. , Baronciani , D. , Andreani , M. , Persini , B. , Erer , B. , Sodani , P. , Manna , M. , Nicolini , G. , Visani , G. and Lucarelli , G. 2002 . Fate of chronic myeloid leukemia patients treated with allogeneic bone marrow transplantation or chemotherapy and/or interferon at a single center: long-term results . Bone Marrow Transplantation , 29 : 1 – 8 .
   PubMed Web of Science ®Google Scholar
• Goldman , J. M. and Druker , B. J. 2001 . Chronic myeloid leukemia: current treatment options . Blood , 98 : 2039 – 2042 .
   PubMed Web of Science ®Google Scholar
• Guilhot , F. , Chastang , C. , Michallet , M. , Guerci , A. , Harousseau , J. L. , Maloisel , F. , Bouabdallah , R. , Guyotat , D. , Cheron , N. , Nicolini , F. , Abgrall , J. F. and Tanzer , J. 1997 . Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. The French Chronic Myeloid Leukemia Study Group . New England Journal of Medicine , 337 : 223 – 229 .
   PubMed Web of Science ®Google Scholar
• Harrold , B. P. 1966. . Syndrome resembling Addison's disease following prolonged treatment with busulphan . British Medical Journal , 5485 : 463 – 464 .
   Google Scholar
• Hehlmann , R. 2000. . Trial of IFN or STI571 before proceeding to allografting for CML? . Leukemia , 14 : 1560 – 1562 .
   PubMed Web of Science ®Google Scholar
• Heinrich , M. C. , Griffith , D. J. , Druker , B. J. , Wait , C. L. , Ott , K. A. and Zigler , A. J. 2000 . Inhibition of c-kit receptor tyrosine kinase activity by STI571, a selective tyrosine kinase inhibitor . Blood , 96 : 925 – 932 .
   PubMed Web of Science ®Google Scholar
• Hilbe , W. , Kuhr , T. , Apfelbeck , U. , Fridrik , M. , Seewann , H. , Stoger , M. , Linkesch , W. , Pont , J. , Baldinger , C. , Hartner , E. , Bernhart , M. , Geissler , D. , Krieger , O. , Lang , A. , Lin , W. , Ludwig , H. , Duba , C. , Greil , R. , Gast , G. and Thaler , J. 2001 . Dose escalation of Ara-C may improve response rates in a subgroup of chronic myeloid leukemia patients with poor response to interferon-α and low-dose Ara-C . Leukemia and Lymphoma , 42 : 1283 – 1288 .
   PubMedGoogle Scholar
• Hochhaus , A. , Reiter , A. , Saußele , S. , Reichert , A. , Emig , M. , Kaeda , J. , Schultheis , B. , Berger , U. , Shepherd , P. C. , Allan , N. C. , Hehlmann , R. , Goldman , J. M. and Cross , N. C. 2000 . Molecular heterogeneity in complete cytogenetic responders after interferon-α therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. The German CML Study Group and the UK MRC CML Study Group . Blood , 95 : 62 – 66 .
   PubMed Web of Science ®Google Scholar
• Holtz , M. S. , Slovak , M. L. , Zhang , F. , Sawyers , C. L. , Forman , S. J. and Bhatia , R. 2002 . Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation . Blood , 99 : 3792 – 3800 .
   PubMed Web of Science ®Google Scholar
• Jacobs , P. , Wood , L. and Fullard , L. 1992 . T-cell depletion by exposure to Campath 1g in vitro virtually abolishes acute graft-versus-host disease . Experimental Hematology , 20 : 715 Abstr.44
   Google Scholar
• Jacobs , P. , Wood , L. , Hale , G. and Waldmann , H. 1997 . Ex vivo T-cell depletion with Campath 1G completely abrogates graft-versus-host disease (GVHD) in peripheral blood stem cell (PBSC) allografts. 26th Annual Meeting International Society for Experimental Hematology, 24–28 August 1997, Cannes, France . Experimental Hematology , 25 : 813 Abstr. 294
   Google Scholar
• Jacobs , P. , Wood , L. , Hale , G. and Waldmann , H. 2000 . Further experience with Campath 1H in monoclonal antibody for T-cell depletion of peripheral mononuclear cells in-the-bag. 5th Congress of the European Haematology Association, 25–28 June 2000, Birmingham, United Kingdom . The Hematology Journal , 1 ( Suppl.1 ) : 192 Abstr.751
   Google Scholar
• Kantarjian , H. , Sawyers , C. , Hochhaus , A. , Guilhot , F. , Schiffer , C. , Gambacorti-Passerini , C. , Niederwieser , D. , Resta , D. , Capdeville , R. , Zoellner , U. , Talpaz , M. and Druker , B. 2002a . Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. The International STI571 CML Study Group . New England Journal of Medicine , 346 : 645 – 652 .
   PubMed Web of Science ®Google Scholar
• Kantarjian , H. M. , Cortes , J. , O'Brien , S. , Giles , F. J. , Albitar , M. , Rios , M. B. , Shan , J. , Faderl , S. , Garcia-Manero , G. , Thomas , D. A. , Resta , D. and Talpaz , M. 2002b . Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase . Blood , 99 : 3547 – 3553 .
   PubMed Web of Science ®Google Scholar
• Kiss , T. L. , Abdolell , M. , Jamal , N. , Minden , M. D. , Lipton , J. H. and Messner , H. A. 2002 . Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantation . Journal of Clinical Oncology , 20 : 2334 – 2343 .
   PubMed Web of Science ®Google Scholar
• Klein , J. P. , Keiding , N. , Shu , Y. , Szydlo , R. M. and Goldman , J. M. 2000 . Summary curves for patients transplanted for chronic myeloid leukaemia salvaged by a donor lymphocyte infusion: the current leukaemia-free survival curve . British Journal of Haematology , 109 : 148 – 152 .
   PubMedGoogle Scholar
• Kurzrock , R. , Kantarjian , H. M. , Druker , B. J. and Talpaz , M. 2003 . Philadelphia chromosome-postive leukemias: from basic mechanisms to molecular therapeutics . Annals of Internal Medicine , 138 : 819 – 830 .
   PubMed Web of Science ®Google Scholar
• Mauro , M. J. , O'Dwyer , M. , Heinrich , M. C. and Druker , B. J. 2002 . STI571: a paradigm of new agents for cancer therapeutics . Journal of Clinical Oncology , 20 : 325 – 334 .
   PubMed Web of Science ®Google Scholar
• McGlave , P. B. , Shu , X. O. , Wen , W. , Anasetti , C. , Nademanee , A. , Champlin , R. , Antin , J. H. , Kernan , N. A. , King , R. and Weisdorf , D. J. 2000 . Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years' experience of the National Marrow Donor Program . Blood , 95 : 2219 – 2225 .
   PubMed Web of Science ®Google Scholar
• McMullin , M. F. , Humphreys , M. , Byrne , J. , Russell , N. H. , Cuthbert , R. J. and O'Dwyer , M. E. 2003 . Chromosomal abnormalities in Ph—cells of patients on imatinib . Blood , 102 : 2700 – 2701 .
   PubMedGoogle Scholar
• Medina , J. , Kantarjian , H. , Talpaz , M. , O'Brien , S. , Garcia-Manero , G. , Giles , F. , Rios , M. B. , Hayes , K. and Cortes , J. 2003 . Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase . Cancer , 98 : 1905 – 1911 .
   PubMed Web of Science ®Google Scholar
• Moodley , S. D. , Jacobs , P. , Ruff , P. , Wood , L. and Sebastian , E. 2001 . Imatinib mesylate (Gleevec) in patients with chronic myelogenous leukaemia in accelerated or blast phase: the South African experience South Africa : SASMO Congress . Abstract
   Google Scholar
• Mugha , T. I. and Goldman , J. M. 2001 . Chronic myeloid leukaemia: STI 571 magnifies the therapeutic dilemma . European Journal of Cancer , 37 : 561 – 568 .
   PubMedGoogle Scholar
• Novartis . 2000. . STI571 News , 1 : 1 – 5 .
   Google Scholar
• Nowell , P. C. and Hungerford , D. A. 1960 . A minute chromosome in human chronic granulocytic leukemia . Science , 132 : 1497
   Web of Science ®Google Scholar
• O'Brien , S. G. , Guilhot , F. , Larson , R. A. , Gathmann , I. , Baccarani , M. , Cervantes , F. , Cornelissen , J. J. , Fischer , T. , Hochhaus , A. , Hughes , T. , Lechner , K. , Nielsen , J. L. , Rousselot , P. , Reiffers , J. , Saglio , G. , Shepherd , J. , Simonsson , B. , Gratwohl , A. , Goldman , J. M. , Kantarjian , H. , Taylor , K. , Verhoef , G. , Bolton , A. E. , Capdeville , R. and Druker , B. J. 2003 . Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. The IRIS Investigators . New England Journal of Medicine , 348 : 994 – 1004 .
   PubMed Web of Science ®Google Scholar
• Olavarria , E. , Hassan , M. , Eades , A. , Nilsson , C. , Timms , A. , Matthews , J. , Craddock , C. , Kanfer , E. , Apperley , J. and Goldman , J. 2000 . A phase I/II study of multiple-dose intravenous busulfan as myeloablation prior to stem cell transplantation . Leukemia , 14 : 1954 – 1959 .
   PubMedGoogle Scholar
• Or , R. , Shapira , M. Y. , Resnick , I. , Amar , A. , Ackerstein , A. , Samuel , S. , Aker , M. , Naparstek , E. , Nagler , A. and Slavin , S. 2003 . Nonmyeloablative allogeneic stem cell transplantation for the treatment of chronic myeloid leukemia in first chronic phase . Blood , 101 : 441 – 445 .
   PubMed Web of Science ®Google Scholar
• Reilly , J. T. 2002. . Class III receptor tyrosine kinase: role of leukaemo-genesis . British Journal of Haematology , 116 : 744 – 757 .
   PubMed Web of Science ®Google Scholar
• Roush , K. S. and Hillyer , C. D. 2002 . Donor lymphocyte infusion therapy . Transfusion Medicine Reviews , 16 : 161 – 176 .
   PubMedGoogle Scholar
• Ruff , P. , Moodley , S. D. , Jacobs , P. , Sebastian , E. and Wood , L. 2001 . Imatinib mesylate (Gleevec) in patients with chronic myelogenous leukaemia (CML) failing or intolerant of interferon-α: the South African experience South Africa : SASMO Congress . Abstract
   Google Scholar
• Sausville , E. A. 2000. . Dragons 'round the fleece again: STI571 versus α1 acid glycoprotein . Journal of the National Cancer Institute , 92 : 1626 – 1627 .
   PubMedGoogle Scholar
• Savage , D. G. and Antman , K. H. 2002 . Imatinib mesylate—a new novel oral targeted therapy . New England Journal of Medicine , 346 : 683 – 693 .
   PubMed Web of Science ®Google Scholar
• Sawyers , C. L. , Hochhaus , A. , Feldman , E. , Goldman , J. M. , Miller , C. B. , Ottmann , O. G. , Schiffer , C. A. , Talpaz , M. , Guilhot , F. , Deininger , M. W. , Fischer , T. , O'Brien , S. G. , Stone , R. M. , Gambacorti-Passerini , C. B. , Russell , N. H. , Reiffers , J. J. , Shea , T. C. , Chapuis , B. , Coutre , S. , Tura , S. , Morra , E. , Larson , R. A. , Saven , A. , Peschel , C. , Gratwohl , A. , Mandelli , F. , Ben-Am , M. , Gathmann , I. , Capdeville , R. , Paquette , R. L. and Druker , B. J. 2002 . Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study . Blood , 99 : 3530 – 3539 .
   PubMed Web of Science ®Google Scholar
• Schindler , T. , Bornmann , W. , Pellicena , P. , Miller , W. T. , Clarkson , B. and Kuriyan , J. 2000 . Structural mechanism for STI-571 inhibition of abelson tyrosine kinase . Science , 289 : 1938 – 1942 .
   PubMed Web of Science ®Google Scholar
• Simonsson , B. , Öberg , G. , Björeman , M. , Björkholm , M. , Carneskog , J. , Gahrton , G. , Hast , R. , Karl , H. , Lanng-Nielsen , J. , Löfvenberg , E. , Malm , C , Turesson , I. , Uden , A. M. , Vilen , L. and Weis-Bjerrum , O. 1996 . Intensive treatment in order to minimize the Ph-positive clone in CML. The Danish-Swedish CML Group . Bone Marrow Transplantation , 17 ( Suppl. 3 ) : S63 – S64 .
   PubMed Web of Science ®Google Scholar
• Talpaz , M. , O'Brien , S. , Rose , E. , Gupta , S. , Shan , J. , Cortes , J. , Giles , F. J. , Faderl , S. and Kantarjian , H. M. 2001 . Phase I study of polyethylene glycol formulation of interferon α-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia . Blood , 98 : 1708 – 1713 .
   PubMedGoogle Scholar
• Talpaz , M. , Silver , R. T. , Druker , B. J. , Goldman , J. M. , Gambacorti-Passerini , C. , Guilhot , F. , Schiffer , C. A. , Fischer , T. , Deininger , M. W. , Lennard , A. L. , Hochhaus , A. , Ottmann , O. G. , Gratwohl , A. , Baccarani , M. , Stone , R. , Tura , S. , Mahon , E. X. , Fernandes-Reese , S. , Gathmann , I. , Capdeville , R. , Kantarjian , H. M. and Sawyers , C. L. 2002 . Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study . Blood , 99 : 1928 – 1937 .
   PubMed Web of Science ®Google Scholar
• Thiele , J. , Kvasnicka , H. M. , Schmitt-Graeff , A. , Spohr , M. , Diehl , V. , Zankovich , R. , Niederle , N. and Leder , L. D. 2000 . Effects of interferon and hydroxyurea on bone marrow fibrosis in chronic myelogenous leukaemia: a comparative retrospective multicentre histological and clinical study . British Journal of Haematology , 108 : 64 – 71 .
   PubMed Web of Science ®Google Scholar
• Thornley , I. , Perentesis , J. P. , Smith , F. O. , Champagne , M. , Lipton , J. M. and Davies , S. M. 2003 . Treating children with chronic myeloid leukemia in the imatinib era: a therapeutic dilemma? . Medical and Pediatric Oncology , 41 : 115 – 117 .
   PubMedGoogle Scholar
• Verweij , J. , Judson , I. and van Oosterom , A. 2001 . STI571: a magic bullet? . European Journal of Cancer , 37 : 1816 – 1819 .
   PubMed Web of Science ®Google Scholar